424,500 Shares in Lifecore Biomedical, Inc. $LFCR Acquired by DCF Advisers LLC

DCF Advisers LLC purchased a new position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 424,500 shares of the company’s stock, valued at approximately $2,229,000. DCF Advisers LLC owned approximately 1.12% of Lifecore Biomedical as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in LFCR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Lifecore Biomedical by 14.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock valued at $104,000 after purchasing an additional 1,886 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Lifecore Biomedical during the second quarter worth approximately $88,000. State of Wyoming purchased a new stake in shares of Lifecore Biomedical during the 2nd quarter worth approximately $69,000. BNP Paribas Financial Markets lifted its position in shares of Lifecore Biomedical by 92.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock worth $43,000 after buying an additional 2,786 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Lifecore Biomedical in the 3rd quarter valued at $28,000. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Stock Up 1.8%

Shares of NASDAQ:LFCR opened at $4.46 on Thursday. The company has a market cap of $168.81 million, a P/E ratio of -4.17 and a beta of 1.08. Lifecore Biomedical, Inc. has a 52 week low of $3.63 and a 52 week high of $8.98. The company has a 50-day moving average price of $4.89 and a 200 day moving average price of $5.34.

Lifecore Biomedical (NASDAQ:LFCR) last issued its earnings results on Wednesday, August 5th. The company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19). The company had revenue of $34.17 million for the quarter, compared to analysts’ expectations of $34.18 million. Analysts expect that Lifecore Biomedical, Inc. will post -1.02 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Barrington Research increased their target price on shares of Lifecore Biomedical from $6.00 to $6.50 and gave the company an “outperform” rating in a research report on Tuesday, June 16th. Wall Street Zen raised shares of Lifecore Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Lifecore Biomedical in a research note on Tuesday, August 4th. Finally, Zacks Research raised Lifecore Biomedical from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.50.

About Lifecore Biomedical

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.